Affiliation:
1. Graduate School, Anhui University of Traditional Chinese Medicine, Hefei, Anhui 230038, China
2. College of Integrated Chinese and Western Medicine, Anhui University of Traditional Chinese Medicine, Hefei, Anhui 230038, China
3. Center of Neurology, Anhui Provincial Hospital of Traditional Chinese Medicine, Hefei, Anhui 230031, China
Abstract
This study is aimed at exploring the possible mechanism of action of the Suanzaoren decoction (SZRD) in the treatment of Parkinson’s disease with sleep disorder (PDSD) based on network pharmacology and molecular docking. Traditional Chinese Medicine Systems Pharmacology (TCMSP) was used to screen the bioactive components and targets of SZRD, and their targets were standardized using the UniProt platform. The disease targets of “Parkinson’s disease (PD)” and “Sleep disorder (SD)” were collected by OMIM, GeneCards, and DisGeNET databases. Thereafter, the protein-protein interaction (PPI) network was constructed using the STRING platform and visualized by Cytoscape (3.7.2) software. Then, the DAVID platform was used to analyze the Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Cytoscape (3.7.2) software was also used to construct the network of the “herb-component-target-pathway.” The core active ingredients and core action targets of the drug were verified by molecular docking using AutoDock software. A total of 135 Chinese herbal components and 41 corresponding targets were predicted for the treatment of PDSD using SZRD. Fifteen important signaling pathways were screened, such as the cancer pathway, TNF signaling pathway, PI3K-AKT signaling pathway, HIF-1 signaling pathway, and Toll-like receptor signaling pathway. The results of molecular docking showed that the main active compounds could bind to the representative targets and exhibit good affinity. This study revealed that SZRD has the characteristics and advantages of “multicomponent, multitarget, and multipathway” in the treatment of PDSD; among these, the combination of the main active components of quercetin and kaempferol with the key targets of AKT1, IL6, MAPK1, TP53, and VEGFA may be one of the important mechanisms. This study provides a theoretical basis for further study of the material basis and molecular mechanism of SZRD in the treatment of PDSD.
Funder
Scientific Research Project of the Chinese National Medical Association
Subject
General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference70 articles.
1. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease
2. Guidelines for the treatment of Parkinson's disease in China (fourth edition);Chinese Journal of Neurology,2020
3. Evaluation of the clinical effect of carbidopa- levodopa controlled- release tablet in the treatment of Parkinsonundefineds disease with sleep disorde;Y. C. Pan;World Journal of Sleep Medicine,2019
4. Role of dopaminergic agonists in the treatment of non-motor symptoms of Parkinson’s disease;Z. Y. Liu;Shanghai Med Pharm,2015
5. Correlations of melatonin and glutathione levels with oxidative stress mechanism in Parkinson’s disease;H. J. Wei;Acta Academiae Medicinae Sinicae,2019
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献